Western blot analysis of extracts from HeLa cells, transfected with 100 nM SignalSilence® Control siRNA (Unconjugated) #6568 (-) or SignalSilence® Aldolase A siRNA I (+), using Aldolase Antibody #3188 and α-Tubulin (11H10) Rabbit mAb #2125. The Aldolase Antibody confirms silencing of aldolase A expression, while the α-Tubulin (11H10) Rabbit mAb is used as a loading control.Learn more about how we get our images
CST recommends transfection with 100 nM SignalSilence® Aldolase A siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 100 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
SignalSilence® Aldolase A siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit aldolase A expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Aldolase (fructose bisphosphate aldolase), a glycolytic enzyme, catalyzes the conversion of fructose 1, 6-bisphosphate to 3-phosphoglyceraldehyde. This ubiquitous enzyme is present as three different isozymes: aldolase A, aldolase B, and aldolase C. Research studies suggest that aldolase A expression potentially differentiates between nonneoplastic liver diseases and hepatocarcinoma (1). Furthermore, investigators have shown that changes in aldolase B gene expression levels have been observed in certain patients with this primary tumor (2,3).
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc. SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Explore pathways related to this product.